These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 23253926)

  • 1. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
    Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
    Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 19 cases.
    Lebel N; Marie I; Grosjean J; Brevet P; Leclercq M; Dumont A; Levesque H; Benhamou Y; Marcelli C; Lequerre T; Vittecoq O
    Clin Exp Rheumatol; 2024 Aug; 42(8):1536-1540. PubMed ID: 38489323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
    Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
    Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort.
    Kuster S; Jordan S; Elhai M; Held U; Steigmiller K; Bruni C; Cacciapaglia F; Vettori S; Siegert E; Rednic S; Codullo V; Airo P; Braun-Moscovici Y; Hunzelmann N; Joao Salvador M; Riccieri V; Gheorghiu AM; Alegre Sancho JJ; Romanowska-Prochnicka K; Castellví I; Kötter I; Truchetet ME; López-Longo FJ; Novikov PI; Giollo A; Shirai Y; Belloli L; Zanatta E; Hachulla E; Smith V; Denton C; Ionescu RM; Schmeiser T; Distler JHW; Gabrielli A; Hoffmann-Vold AM; Kuwana M; Allanore Y; Distler O;
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience.
    Castellví I; Elhai M; Bruni C; Airò P; Jordan S; Beretta L; Codullo V; Montecucco CM; Bokarewa M; Iannonne F; Balbir A; Hsu VM; Distler O; Matucci-Cerinic M; Allanore Y;
    Semin Arthritis Rheum; 2020 Dec; 50(6):1489-1493. PubMed ID: 32165035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
    PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus.
    Ikeda K; Sanayama Y; Makita S; Hosokawa J; Yamagata M; Nakagomi D; Takabayashi K; Nakajima H
    Clin Dev Immunol; 2013; 2013():697525. PubMed ID: 24324510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
    Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
    Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
    Zacay G; Levy Y
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique.
    Distler JH; Jordan S; Airo P; Alegre-Sancho JJ; Allanore Y; Balbir Gurman A; Caporali R; Caramaschi P; Carreira PE; Chizzolini C; Cutolo M; Tuncay Duruöz M; Farge-Bancel D; Hesselstrand R; Iannone F; De Keyser F; Kucharz EJ; Launay D; García de la Peña Lefebvre P; Lukacova O; Marasini B; Martinovic D; Marques Neto JF; Radic M; Rednic S; Riemekasten G; Rovensky J; Seidel MF; Senel S; Smith V; Sunderkötter C; Ton E; van Laar JM; Matucci-Cerinic M; Müller Ladner U; Distler O
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S40-5. PubMed ID: 21586217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
    Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
    Massarotti EM
    Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis.
    Omair MA; Phumethum V; Johnson SR
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S55-9. PubMed ID: 22691210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept induces clinical improvement in patients with severe systemic sclerosis.
    de Paoli FV; Nielsen BD; Rasmussen F; Deleuran B; Søndergaard K
    Scand J Rheumatol; 2014; 43(4):342-5. PubMed ID: 25088011
    [No Abstract]   [Full Text] [Related]  

  • 20. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.